2017 Press Releases

Webcast ImageWebcast
Q4 2016 Aeglea Biotherapeutics, Inc. Earnings Conference Call (Live)
03/23/17 at 4:30 p.m. ET
Q4 2016 Aeglea Biotherapeutics, Inc. Earnings Conference Call
Thursday, March 23, 2017 4:30 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Keyword Search
 
2017 | 2016 | 2015
DateTitle 
03/23/17Aeglea BioTherapeutics to Present Topline Data from Phase 1 Trial of AEB1102 for Treatment of Arginase I Deficiency at 2017 ACMG Annual Clinical Genetics Meeting
AUSTIN, Texas, March 23, 2017 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare genetic diseases and cancers, today announced topline data from a Phase 1 open-label study evaluating the safety and tolerability of its lead product candidate, AEB1102, for patients with Arginase I deficiency. The poster, entitled “Initial Results of a Phase I Open-Label Study... 
03/17/17Aeglea BioTherapeutics to Announce Fourth Quarter and Full-Year 2016 Financial Results on Thursday, March 23
Company to host conference call and webcast to provide business update and review topline Phase 1 Arginase I deficiency clinical results AUSTIN, Texas, March 17, 2017 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare genetic diseases and cancer, today announced that it will report its financial results for the quarter and year ended December 31, 2016 on T... 
02/28/17Aeglea BioTherapeutics to Present Preclinical Data for AEB1102 at Keystone Symposia Conference on Tumor Metabolism
AUSTIN, Texas, Feb. 28, 2017 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare genetic diseases and cancer, today announced that it will present at the 2017 Keystone Symposia Conference on Tumor Metabolism: Mechanisms and Targets, taking place March 5 – 9 in Whistler, British Columbia. Details of the presentation, which will be delivered both orally and a... 
02/16/17Aeglea BioTherapeutics Appoints Dr. Suzanne Bruhn to Board of Directors
AUSTIN, Texas, Feb. 16, 2017 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare genetic diseases and cancer, today announced the appointment of Suzanne L. Bruhn, Ph.D. to its Board of Directors. Dr. Bruhn previously served as chief executive officer, president and director at Promedior, Inc., a clinical-stage biotechnology company, from 2012 to 2015. “Su... 
01/17/17Aeglea BioTherapeutics to Present New Data at 2017 ACMG Annual Clinical Genetics Meeting
Presentation includes positive initial data from Phase 1 clinical study of AEB1102 for the treatment of Arginase I deficiency AUSTIN, Texas, Jan. 17, 2017 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare genetic diseases and cancer, today announced that it will present new clinical and research data in two presentations at the 2017 American College of Me...